Business
ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update
LYON, France, October 15, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the third quarter of 2025 and provides a business update.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/3664e96ae0bbc19a422f0095b207ac5c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ub3er1S9L6crMuOdXGZThA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3664e96ae0bbc19a422f0095b207ac5c","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/W6TmwNATQgOluKOTuPZnSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3664e96ae0bbc19a422f0095b207ac5c","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €13.4 million as of September 30, 2025","length":55,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Current cash position secures runway until Q2 2026","length":50,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro in people with Type 1 Diabetes and Type 2 Diabetes","length":145,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":377,"olType":false},{"type":"text","content":"LYON, France, October 15, 2025--(BUSINESS WIRE)--Regulatory News:","length":65,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the third quarter of 2025 and provides a business update.","length":320,"tagName":"p"},{"type":"text","content":""The clinical success of BioChaperone® Lispro ultra-rapid insulin demonstrates Adocia's ability to invent and develop a product as complex as prandial insulin. I would like to thank Adocia’s and Tonghua Dongbao’s teams for the high quality of execution of this Phase 3 trial. The century-long history of insulin development shows that innov...